SEKISUI's Strategic Investment in Biopharmaceutical Manufacturing
SEKISUI Diagnostics has made a significant move to enhance its microbial Contract Development and Manufacturing Organization (CDMO) capabilities. With a substantial investment of £15.7 million, which equates to approximately $20.7 million, the company is expanding its cGMP capacity at its UK facility. This expansion aims to enable the clinical-grade manufacturing of various drug substances for an array of biopharmaceutical products.
New Manufacturing Capabilities to Meet Demand
Once the necessary licensing is complete, this upgraded facility will facilitate the manufacturing of critical drug types, including enzymes, proteins, antibody fragment therapies, as well as plasmids and enzymes used in advanced gene therapies. This intends to position SEKISUI as a key player in a field where demand is currently surpassing available manufacturing capacity.
BioProduction Services by SEKISUI
SEKISUI's BioProduction service specializes in fermentation and is designed for companies looking to collaborate with an experienced provider. The firm’s microbial process development expertise greatly simplifies both technical transfer and the scale-up of manufacturing processes. The upgraded facility now includes Grade C microbial fermentation and purification suites capable of supporting production scales of up to 1,000 liters.
Leadership Insights on Growth
Robert Schruender, the President and CEO of SEKISUI Diagnostics, emphasized the strategic importance of this investment, stating, "This investment supports the vision and mission of SEKISUI Diagnostics and the broader SEKISUI Medical Group by enabling the continued growth of our share of the biologics CDMO market." Schruender expressed optimism about future partnerships with biopharma companies in need of dedicated manufacturing support.
Commitment to Excellence
Louise Digby, the Vice President of Enzymes & BioProduction at SEKISUI Diagnostics, added that years of honing technical and operational expertise in enzyme production and microbial fermentation have positioned the company well to meet the evolving needs of their customers worldwide. The cGMP expansion not only broadens their service offerings but also enhances support for existing customer partnerships.
About SEKISUI Diagnostics
SEKISUI Diagnostics is a part of the larger SEKISUI Medical Group, boasting over 40 years of experience in providing innovative medical diagnostics around the globe. Their diverse product offerings encompass clinical chemistry reagents, point-of-care tests, pre-analytic systems, enzymes, specialty biochemicals, and their robust microbial CDMO business, known as BioProduction by SEKISUI.
SEKISUI Medical Group Overview
SEKISUI Medical Group encompasses a broad, diverse network that integrates diagnostics with pharmaceutical sciences, covering numerous facets such as drug development services and manufacturing. Their offerings include active pharmaceutical ingredients, pharmaceutical intermediates, amino acids, and a vast selection of enzymes for diagnostic applications, as well as biopharmaceutical contract manufacturing.
Frequently Asked Questions
What is SEKISUI's recent investment for?
The recent £15.7 million investment by SEKISUI is aimed at expanding their cGMP biopharmaceutical manufacturing capabilities in the UK.
What types of products will the new facility manufacture?
The facility will manufacture a range of products including enzymes, proteins, antibody fragment therapies, plasmids, and enzymes for gene therapy.
Why is this expansion necessary?
This expansion is essential to meet the growing demand for biopharmaceuticals and to enhance SEKISUI's market position in the biologics CDMO sector.
What is BioProduction by SEKISUI?
BioProduction by SEKISUI is a service offering specializing in fermentation processes, focusing on proteins and downstream purification.
How does SEKISUI support its partners?
SEKISUI supports its partners through comprehensive technical transfer and process scale-up, using their extensive expertise in microbial fermentation and production.
